Compare Honest Company Inc (HNST) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs ResMed Inc. — how do they compare? Honest Company Inc trades at $3.89 (market cap $426.55M), while ResMed Inc. trades at $196 (market cap $28.81B). The key difference: ResMed Inc. is far larger — about 67.5× Honest Company Inc's market cap, and ResMed Inc. pays a 1.21% dividend while Honest Company Inc pays none. Which is the better fit depends on your goals.
| HNST | RMD | |
|---|---|---|
Market Cap | $426.55M | $28.81B |
Sector | Consumer Staples | Health |
52-Week High | $4.95 | $293.73 |
52-Week Low | $2.10 | $182.82 |
Enterprise Value | $347.95M | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $3.87, up 1.04% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.01, meeting estimates, but has missed expectations in two of the last three quarters. Revenue declined to $371.32 million in 2025 from $378 million in 2024, with a net loss of $15.69 million. Positive cash flow from operations of $15.12 million and record gross margins near 34% highlight operational improvements amid challenges.
The outlook remains mixed; analyst consensus is cautious with 30% buy ratings. Upside potential exists from gross margin expansion and cost controls, but risks include persistent net losses, competitive pressures in personal care, and reliance on retail channel growth. Investor sentiment is neutral, pending sustained profitability and revenue stabilization in 2026.
ResMed (RMD) trades at $198.61, down 0.19% on the day, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals, with Q1 2026 EPS beating estimates at $2.86 and revenue growth from $5.15B in 2025 to a projected $5.5B in 2026. Recent news highlights the sale of its MatrixCare business for $490 million, sharpening focus on core sleep and respiratory care markets. Analyst consensus is a Buy with a $245.88 price target, implying significant upside.
The outlook for RMD is positive, driven by consistent earnings beats, robust cash flow growth, and strategic divestitures. Key opportunities include market leadership in sleep apnea and digital health innovation. Risks involve competitive pressures from GLP-1 drugs and macroeconomic headwinds. Institutional sentiment is mixed but leans bullish on long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
